A new tool to stage Parkinson’s disease PDCS (Parkinson’s disease composite scale): A pilot study on behalf of the European Parkinson’s disease association (EPDA)
Objective: The aim of PDCS is to create a simple scale able to measure the severity of patients, taking into account cardinal motor, non motor…Pantotenate kinase associated neurodegeneration (PKAN): Proposal for a clinical rating scale
Objective: To design and validate a quantitative method for the assessment of PKAN patients. Background: Despite advances in the research of novel therapies for PKAN,…Syndrome of dystonia-parkinsonism is a complication of cyclosporine A treatment and may be irreversible
Objective: To describe the clinical and imaging features of patients who developed dystonia-parkinsonism syndrome due to cyclosporine A(CsA). Background: CsA is an immunosuppressant widely used…A comparison of standards of care in Parkinson’s disease between a general neurology clinic and a specialist movement disorders clinic based on the UK NICE guidelines
Objective: To compare standards of care for patients with Parkinson's disease (PD) between a general neurology clinic and specialist movement disorders clinic based on the…Elemental profiles as biomarkers for diagnosis and disease progression of Parkinson’s disease
Objective: This study aims to analyse the elemental profiles in the cerebrospinal fluid (CSF) of patients with idiopathic Parkinson´s disease (PD) and age-matched control patients…PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program
Objective: To determine if outcomes following a PT program are improved if PT sessions are conducted while PD patients are in an on motor state…Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Objective: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for Parkinson's disease (PD). Background: Despite decades of intensive research, to date,…A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients
Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients
Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…Body position during sleep in patients with Parkinson’s disease (PD): A sensor-based analysis
Objective: To identify the body position during sleep in PD patients in comparison to their spouses by using multisite wearable inertial sensors. Background: Nocturnal hypokinesia…
- « Previous Page
- 1
- …
- 334
- 335
- 336
- 337
- 338
- …
- 405
- Next Page »